Sundar, Shyam ; Chakravarty, Jaya (2010) Liposomal amphotericin B and leishmaniasis: dose and response Journal of Global Infectious Diseases, 2 (2). pp. 159-166. ISSN 0974-777X
Full text not available from this repository.
Official URL: http://www.jgid.org/article.asp?issn=0974-777X;yea...
Abstract
Liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). It is the treatment of choice for immunocompetent patients in the Mediterranean region and the preferred drug for HIV/VL co-infection. Although there is a regional variation in the susceptibility of the parasite a total dose of 20 mg/kg is effective in immunocompetent patients. Randomized clinical trials of liposomal amphotericin B in the treatment and secondary prophylaxis of HIV-VL coinfected patients is urgently needed to optimize treatment in this subset. With the availability of Liposomal amphotericin B at a preferential pricing in the endemic areas, short course combination therapy can become a viable alternative.
Item Type: | Article |
---|---|
Source: | Copyright of this article belongs to Medknow Publications. |
Keywords: | Kala-azar; Liposomal; Amphotericin B |
ID Code: | 71389 |
Deposited On: | 24 Nov 2011 11:12 |
Last Modified: | 25 Nov 2011 07:41 |
Repository Staff Only: item control page